Health systems are stewards of patient electronic health record (EHR) data with extraordinarily rich depth and breadth, reflecting thousands of diagnoses and exposures. Measures of genomic variation integrated with EHRs offer a potential strategy to accurately stratify patients for risk profiling and discover new relationships between diagnoses and genomes. The objective of this study was to evaluate whether Polygenic Risk Scores (PRS) for common cancers are associated with multiple phenotypes in a Phenome-wide Association Study (PheWAS) conducted in 28,260 unrelated, genotyped patients of recent European ancestry who consented to participate in the Michigan Genomics Initiative, a longitudinal biorepository effort within Michigan Medicine. PRS for 12 cancer traits were calculated using summary statistics from the NHGRI-EBI GWAS catalog. A total of 1,711 synthetic case-control studies was used for PheWAS analyses. Patients with at least one cancer diagnosis constituted 13,490 patients. PRSs exhibited strong association for several cancer traits they were designed for including female breast cancer, prostate cancer and melanomas of skin.
Introduction
In the past decade, genome-wide association studies (GWAS) using single nucleotide polymorphisms (SNPs) led to discovery of many common disease susceptibility loci [1] [2] [3] .
An alternative agnostic way of exploring gene-disease association is through phenomewide association studies (PheWAS) [4] [5] [6] . PheWAS enable simultaneous exploration of the association between genetic variants and a broad spectrum of physiological/clinical phenotypes. To explore the joint genome x phenome landscape one needs access to both Electronic Health Records (EHRs) and GWAS data. The promise and potential of these studies have recently been illustrated by the electronic Medical Records and Genomics (eMERGE) network 7; 8 . Beyond genetic associations, EHR has enabled discovery of new associations between disease and secondary effects of drugs or blood biomarker levels [9] [10] [11] .
PheWAS have been used to both replicate known genetic-phenotypic associations and to discover new consequences for disease associated variants. PheWAS use computable phenotypes derived from EHR databases. Traditional PheWAS have used International Classification of Disease (ICD) codes to define a set of computable phenotypes or "PheWAS codes" defined and validated by experts using a combination of ICD codes 12 . Standard PheWAS have primarily focused on correlating genetic variants, one at a time, to a spectrum of phenotypes. When each variant is associated with a small effect size, these studies can only provide limited insight. For this reason, many areas of genetics now use ensembles of variants that cumulatively explain substantial variation in disease risk [13] [14] [15] . For example, polygenic risk scores (PRS) constructed from multiple GWAS identified loci have been proposed for cancer screening, risk prediction and risk stratification [16] [17] [18] [19] .
In this paper, we introduce the new concept of PheWAS based on a PRS instead of a single genetic variant. We construct PRS for multiple cancers including some of the Our study is based on the Michigan Genomics Initiative (MGI) launched in 2012, a biorepository effort to create a longitudinal cohort of participants in Michigan Medicine.
MGI enrolled participants undergoing anesthesia prior to a surgery or diagnostic procedure, creating a patient community with genome-wide data, electronic health information, and permission for follow-up and re-contact in future studies. Our current analysis of 28,260 patients in MGI indicates that 47.7% of these patients have at least one current or previous neoplasm diagnosis (excluding benign neoplasms). This presents a unique opportunity to study multiple cancer outcomes leveraging both EHR and genomic data in MGI.
At the same time, this enrichment of cancer patients in MGI highlights some of the special features of the sampling frame for the study and source population. Because of the self-selective, consent-based nature of MGI patient enrollment, the sample selection mechanism is non-probabilistic, that is, the probability of a sampling unit being included in the study is not pre-determined. The MGI sample is enriched for neoplasm diagnoses which could be related to the fact that many surgeries are diagnostic procedures specifically indicated for cancer treatment and screening (e.g., colonoscopy, skin biopsies). Cancer patients undergo surgery more frequently than the general population and frequently choose an academic medical center for diagnostic and/or interventional procedures. The analytic framework presented in this paper conducts careful sensitivity analysis for protecting our inference against such selection biases, unbalanced casecontrol ratios, and phenotypic enrichment.
There are several innovative aspects to our study. Our study represents the first comprehensive phenome-wide association analysis focused on using PRS in a cancerenriched cohort accrued in an academic health center. Our study is also the first PheWAS focused on cancer. Our results demonstrate PRS, a summary score constructed based on results of large population-based GWAS, as a biomarker that enables useful cancer risk stratification among patients in an academic medical center.
We also observe that when a PRS-based PheWAS leads to the association of a cancerspecific PRS (e.g., prostate cancer PRS) with other secondary related phenotypes (e.g., erectile dysfunction or urinary incontinence), these findings may require careful consideration. We observe that many of these secondary associations are often driven ancestry (~90% of participants) were defined as samples that fell into a circle that spanned the European populations of the HGDP panel in the PC1 versus PC2 space.
Principal components were stored and used for further association tests. After quality control, 28,260 unrelated, genotyped individuals of recent European ancestry with age and ICD9 data remained for further analysis.
Phasing and Genotype Imputation
We imputed genotypes of the Haplotype Reference Consortium using the Michigan Imputation Server 26 and filtered poorly imputed variants with R 2 <0.3 and/or minor allele frequency (MAF) < 0.1% resulting in over 17 million well-imputed variants. The obtained accuracy for imputed variants, i.e. the average empirical R 2 values for different MAF frequency bins, was: 0.89 (0.1%<=MAF≤0.5%), 0.94 (0.5%<MAF≤5%), and 0.96 (MAF>5%).
Phenome Generation
We extracted the ICD9 data for 28,260 unrelated, genotyped individuals of recent European ancestry and mapped 3,5 million ICD9 codes to PheWAS codes (PheWAS translation table version 1.2) 12 . The ICD9 codes (10,322 unique ICD9 codes) were aggregated to PheWAS traits using the PheWAS R package. Cases for a given PheWAS code were defined if an individual had at least one assignment of that PheWAS code in their record. The remaining individuals that did not have overlapping PheWAS codes of exclusion criteria were considered controls. A total of 1,857 case control studies were generated of which 1,711 with ≥ 20 cases were used for further analyses (see Table S1 ; phenotypes with < 50 cases were coded as "<50").
GWAS Catalog SNP Extraction and Construction of PRS
We downloaded previously reported GWAS catalog variants from the NHGRI-EBI Catalog (file date: June 31, 2017) 27 . Variant positions were converted to GRCh37 using variant IDs from dbSNP version 144 (UCSC genome browser) after updating outdated dbSNP IDs to their merged dbSNP IDs. Entries with missing risk alleles, risk allele frequencies, or odds ratios were excluded. We corrected strand flips so that the reported risk allele matched one of the alleles found at the corresponding position in the 1000 Genomes Project data. We only included entries with broad European ancestry (as reported by the NHGRI-EBI Catalog) to allow an additional quality control check by comparing the reported risk allele frequencies (RAF) in controls with the frequencies of the 503 European samples of the 1000 Genomes Project reference data (Phase 3, release 5) 28 , and then excluded entries whose RAF deviated more than 15% from the reference. For each analyzed cancer type, we extracted overlapping GWAS hits in our genotype data and estimated pairwise LD (r 2 ) using the available allele dosages of the matched controls. For pairwise correlated SNPs (r 2 >0.5) or SNPs with multiple entries, we kept the SNP with the younger publication date (and smaller P value, if necessary) and excluded the other (Figure S1 & Table S2 ). Finally, we calculated risk allele counts as the sum of allele dosages of risk SNPs of the risk increasing alleles and weighted the allele dosages of risk SNPs of the risk increasing alleles with the logs of their reported odds ratios and calculated PRS as their sum. Namely, for subject j in MGI the PRS was of the form PRS j =∑ ߚ ‫ܩ‬ where the sum extends over all included loci, ߚ or the log odds ratios were retrieved from the GWAS catalog for locus i and ‫ܩ‬ was the measured dosage data for the risk allele on locus i in subject j. This variable was created for each MGI participant.
Statistical Analysis
For the current study, we initially explored 30 cancer traits that had matching entries in the GWAS catalog (Table S3) , and restricted our analysis to 12 cancer traits with at least 5 risk SNPs detected in the GWAS catalog after filtering that had relatively larger samples sizes in MGI (namely N≥250 cases) ( Table 2) .
To estimate the association of PRS with the primary cancer phenotype, we first determined the PRS quartiles using all control samples, categorized all samples according to these PRS quartiles and fitted Firth bias corrected logistic regression adjusting for age, sex, genotyping array, and the first four principal components to obtain odds ratio corresponding to the top versus the bottom quartile PRS (reference), referred to as PRS OR.
To compare reported associations of GWAS catalog SNPs with association observed in the MGI data set, we tested the association between reported GWAS hits and its corresponding trait using Firth bias-corrected logistic likelihood implemented in EPACTS (version 3.3, see Web Resources). Age, sex, genotyping array, and principal components 1-4 were included as covariates (see Kinship and Ancestry Inference).
To determine the agreement of estimated effect sizes [estimated log(odds ratios)] between the MGI case-control studies and the published GWAS catalog hits, we estimated Pearson's correlation coefficient [ߩ ො ] between the two sets of coefficients.
Towards more standard discovery type genome-wide association analysis with MGI data, we performed genome-wide logistic regression analysis for the 9 cancer traits where we observed strong correlation between GWAS catalog and MGI effect estimates Table 2 ). For scalable GWAS analysis we used fast association tests by using the saddle point approximation method 32 adjusting for age, sex, genotyping array, the first four principal components and only included SNPs with MAF>0.1%.
For our primary PRS-PheWAS, for the six PRS in Table 2 that showed strong and significant association, we conducted Firth bias corrected logistic regression by fitting a model of the following form and repeated them for each of the 1,711 phenotypes. logit (P(Disease=1|PRS, Age, Sex, Array, PC)
Where the PCs were the first four principal components obtained from the principal component analysis of the genotyped GWAS markers and where "Array" represents the two genotyping array versions accounting for potential batch effects. To adjust for multiple testing, we applied the conservative phenome-wide Bonferroni correction according to the 1,711 analyzed PheWAS codes (Table S1 ). Through a PheWAS plot, we present -log10 (P-values) corresponding to each of the 1,711 association tests for ‫ܪ‬ :
. Firth's bias correction method was applied to all single SNP and PRS models to resolve the problem of separation in logistic regression (R package "logistf") 29; 30 . Directional arrows on the PheWAS plot indicate whether a phenome-wide significant trait was positively or negatively associated with the PRS.
Furthermore, our sensitivity analyses included similar models using the unweighted risk allele counts as predictor to consider effect orientation regardless of effect size as well as conditional logistic regression on matched case control studies to check if differences in age or sex distributions or extreme case -control ratios influenced the main analysis.
We performed matching using the R package "MatchIt" and applied nearest neighbor matching for age, PC1-4 (Mahalanobis-metric matching; matching window caliper/width of 0.25 standard deviations) and exact matching for sex, limiting the maximal number of controls per case to 10. 31
To follow-up on the observed phenome-wide significant associations and investigate the possibility of the secondary trait associations with PRS being completely mediated through the primary trait association, we performed a second set of PheWAS after excluding individuals affected with the primary cancer trait underlying the PRS, namely the "exclusion PRS PheWAS". We applied "exclusion PRS PheWAS" instead of a PRS PheWAS conditioned on the primary cancer trait as the control exclusion criteria implemented in the PheWAS phenotype construction pipeline will often eliminate these primary cancer cases from being eligible controls for some selected secondary related phenotypes and thus a logistic analysis will lead to complete separation 12 . We also stratified the MGI data set (or the corresponding gender subset depending on cancer type) into ten equally sized PRS deciles and determined the percentage of observed cases in each risk decile and conducted a test of significance in difference in proportions across the deciles before and after removing individuals affected with cancer traits related to the primary cancer trait.
If not stated otherwise, analyses were performed using R 3.4.1 33
Results
In the current study, we report results obtained from 28,260 genotyped and unrelated samples of inferred European ancestry with available integrated ICD9-based EHR data ( Table 1) . We conducted our initial analysis on 12 cancer traits that after quality control had at least five independent risk variants in the NHGRI EBI GWAS Catalog and more than 250 cases in our cohort ( Table 2 , Table S2 ). Table 2 summarizes data on 8, 423 distinct individuals that were affected by at least one of the 12 cancers. Of these, 6,398 had one cancer, 1,574 had two cancers, and 451 had more than two cancer sites involved.
Correspondence of MGI effect estimates with those reported in GWAS:
To assess the calibration properties of the 12 ICD-9 based cancer case-control studies, we first compared the concordance of observed effect estimates (log odds ratios) from MGI with published effect estimates reported in the NHGRI EBI GWAS catalog.
We found strong positive correlation ( Figure S2 ).
Cancer GWAS in MGI:
After having established strong positive correlation for 9 of the 12 cancer traits (see above) and thus a phenotype quality that might be in line with their corresponding published GWAS, we performed for each of these 9 cancers a GWAS to explore our capability to replicate and/or uncover cancer risk variants in a genome-wide setting. We found genome-wide significant signals (P<5x10 -8 ) for female breast cancer, melanoma of skin, basal cell carcinoma, squamous cell carcinoma and thyroid cancer.
All but one of the genome-wide signals were discovered in loci already reported in the GWAS catalog for the corresponding cancer trait or related phenotypes. For instance, the four melanoma of skin loci with risk variants near SLC45A2 (MIM 606202), IRF4
(MIM 601900), MC1R (MIM 155555) and ASIP/RALY (MIM: 600201) were previously reported to be associated with melanoma, non-melanoma skin cancer, squamous cell carcinoma, or basal cell carcinoma [34] [35] [36] [37] [38] . Also, the two breast cancer risk loci near Figure S3 .
Owing to the smaller sample sizes compared to the studies included in the NHGRI-EBI GWAS catalog, only 8 of 320 catalog SNPs exceeded the genome-wide significance (Table S5 ). However, we found catalogued risk SNPs in Table 2 were markedly enriched in the top 1% of GWAS associations, especially for the larger case/control studies. For example, 27 out of the 93 GWAS catalog PCa risk SNPs fall in Top 1% of associated SNPs in the MGI GWAS (with P<0.0083) ( Table S6) . Table S3 ). We excluded the remaining six cancer traits from further investigation, because in this initial analysis they showed only little or moderate enrichment (PRS OR < 1.5) and consequently only modest power for subsequent exploration of phenome-wide associations ( Table 2) .
Reproducibility of PRS Primary Cancer association:

PRS PheWAS:
Next, we evaluated each of the six remaining PRS that were strongly associated with the primary trait across a collection of 1,711 EHR-derived phenotypes (not limited to cancer traits) with at least 20 cases each (Table S1 ). For each of the six cancer PRS, we found strongest associations with their primary traits, except for squamous cell carcinoma PRS which revealed its strongest association with the more general skin cancer trait definition (P PRS = 5.8x10 -62 ) (Figure 2) . We conducted sensitivity analyses of the reported results where we created 1:10 matched (for age, sex and first four PCs) case control studies. We also applied unweighted sum of risk allele counts instead of weighted PRS ( Table S7 ). The results remained robust with respect to sampling strategy and effect size weighting.
In addition, we identified for each PRS novel associations with secondary traits besides their primary traits (Figure 2 A-F, Table S7 ). For example, we observed associations of the three skin cancer PRSs (PRS for melanoma, basal cell carcinoma, and squamous cell carcinoma) with skin cancer and skin cancer sub categories -expected due to their overlapping SNP sets -but also significantly associated with dermatologic phenotypes, e.g. actinic keratosis (P PRS < 4.5x10 -6 ) and other degenerative skin conditions or disorders, all potential pre-cancer stages (Figure 2C,D,E) .
Similarly, the female breast cancer PRS was associated not only with breast cancer (P PRS =8.4x10 -37 ) but also with acquired absence of breast (P PRS =6.0x10 -13 ), abnormal mammogram (P PRS =1.2x10 -8 ), benign neoplasms of the breast (P PRS =1.5x10 -7 ) and benign mammary dysplasias (P PRS =1.1x10 -5 ) (Figure 2A) . The PRS originally constructed for prostate cancer associated with prostate cancer (P PRS =2.4x10 -65 ), as expected, but also with four additional traits: elevated prostate specific antigen (P PRS =3.5x10 -26 ), erectile dysfunction (P PRS =8.4x10 -15 ), urinary incontinence (P PRS =9.5x10 -11 ), frequency of urination and polyuria (P PRS =3.6x10 -6 ), and hyperplasia of prostate Table S7 ).
While all of the above mentioned secondary trait associations were in the same effect orientation as their primary traits, i.e. increasing PRSs were associated with increased risk for the secondary trait, we observed an association of increasing thyroid cancer PRS with decreased risk for hypothyroidism (P PRS =1.2x10 -9 ) ( Figure 2F ).
Exploring Secondary PRS PheWAS Associations via Exclusion PRS PheWAS:
To further explore the secondary associations in PRS PheWAS (Figure 2) , we performed exclusion PRS PheWAS by removing samples affected with the cancer or related cancer traits of its corresponding PRS. After removing all breast cancer cases (N = 1,894) no association with breast cancer PRS remained significant, e.g. acquired absence of breast (P PRS = 0.98), abnormal mammogram (P PRS = 0.51) or benign neoplasms of the breast (P PRS = 0.98), indicating complete mediation of the secondary trait associations through the primary trait ( Figure S4A) . We made similar observations for prostate cancer PRS were none of the previously detected secondary trait associations remained phenome-wide significant after removing all 1,425 prostate cancer cases (Figure S4B) .
In contrast, we found a markedly stronger association between hypothyroidism and thyroid cancer PRS after removing 472 thyroid cancer cases (P PRS = 1.4x10 -18 ) compared to the full analysis (P PRS = 1.2x10 -9 ) which corresponded to the reversed effect orientations between thyroid cancer PRS and hypothyroidism (Figure 2F) .
To account for the substantial overlap between skin cancer sub types, e.g. 253 of the 1,404 individuals affected with melanoma are also affected by basal and/or squamous cell carcinoma ( Figure S5) To further understand the discovered associations in the PRS PheWAS analyses (Figure 2 and Figure S4 ), we conducted a simple follow-up analysis by stratifying the data into PRS deciles. We only discuss selected secondary trait associations for the prostate cancer (PCa), squamous cell carcinoma (SCC) and thyroid example in the main text and relegate their comprehensive analysis and a similar analysis of breast cancer, melanoma and basal cell carcinoma PRS to the supplemental material (Table   S8 ). For prostate cancer, we stratified a total of 12,026 male individuals in MGI with age ≥ 30 years into deciles of PCa PRS. The observed PCa PRS associations in the PheWAS analysis are further supported by their respective increasing trait prevalences that are observed across 10 PCa PRS decile-stratified strata (Figure 3A ; Table S8 ).
These strata were not adjusted for confounders, but it is less likely that PRS is strongly associated with other covariates. A striking observation is that the proportion of PCa P=0.90). Based on these observations, we hypothesize that PCa likely mediates the association of PCa PRS on the secondary traits ePSA, ED, and UI, through either prior symptoms of PCa or prescribed medication, chemotherapy or surgical procedures for prostate removal (Table S8) .
For SCC PRS stratification, there was a gradual increase of individuals affected with SCC with increasing PRS risk deciles, a trend that was also noted for actinic keratosis, dermatitis due to solar radiation, and seborrheic keratosis (Figure 3B) (Table S8) . Several studies previously reported genetic overlap of a subset of thyroid cancer risk variants and variants associated with serum levels of thyroid stimulating hormone (TSH) which matches the current observed association between thyroid cancer risk and risk for hypothyroidism 41; 42 .
Discussion
Integration of large-scale biorepositories such as genetic data with EHRs are becoming increasingly common and indispensable for next-generation etiology studies. In this paper, we proposed, demonstrated and tested trait-specific polygenetic risk scores (PRS) that summarize the results of large population-based GWAS studies towards cancer risk prediction in an actual academic medical center population managed by Michigan Medicine. Data repositories like MGI, allow us to explore many traits simultaneously whereas population-based case-control studies focus on one specific trait. It is indeed encouraging that the results of population-based studies corroborate with the phenotypes computed from EHR data. We found improved trait prediction power of the composite PRS compared to single-SNP analyses. We also reproduced catalogued associations of SNPs for some cancer traits, observed excellent correspondence of effect estimates and discovered novel secondary trait associations that were not mediated through the primary cancer diagnoses. To our knowledge this is the first PRS PheWAS study and the first PheWAS study focused on cancer.
We have introduced several novel analytic strategies in this paper. We presented a principled framework and quality-control pipeline to create a PRS from a large curated, public database and to perform PRS PheWAS in a potentially biased sample. We introduced a primary PheWAS using Firth's bias-reduced logistic regression which has the advantage of resolving the problem of separation in logistic regression and providing well-controlled type I error rates for unbalanced case control studies with relatively small sample counts 29; 30; 44 , that are often present in large EHR-based phenomes where controls are frequently hundredfold more abundant than cases. In addition, we conducted thorough sensitivity analyses to check the robustness of our findings by using PheWAS with unweighted risk allele counts and PRS PheWAS based on matched controls. All our reported results remained robust under sensitivity analysis.
To differentiate between PRS association that truly derive from a shared genetic risk profile from secondary associations that are potentially mediated through the primary trait, (for example urinary incontinence or erectile dysfunction following prostate cancer treatment) we further introduced a follow-up PRS PheWAS approach that excludes the
PRS's underlying cancer traits. While reducing overall sample size, this "exclusion
PheWAS" approach is statistically preferable in contrast to a PRS PheWAS that conditions on the primary cancer trait. A conditional PheWAS approach is often affected by unilaterally applied exclusion criteria of controls that occur during defining a PheWAS code, e.g. PCa cases were excluded from being eligible controls for elevated PSA levels and vice versa. Our approach also could directly discard mediated trait associations and lead to the re-discovery of traits that may be useful for presymptomatic cancer screening: thyroid hormone levels for thyroid cancer and actinic keratosis for squamous cell carcinoma. Further exploration of our findings in larger biobank studies, like the UK Biobank study, is warranted and will empower a deeper understanding of relevant pre-cancer traits 45 .
There are several limitations to the current study. We decided to rely on the associations reported in the NHGRI-EBI GWAS catalog instead of focusing on the latest and largest GWAS study specific for each cancer trait. We acknowledge that the implemented curation of GWAS findings delays inclusion of the latest publications which would offer a more complete sets of genetic risk factors and more precise effect estimates. However, the NHGRI-EBI GWAS catalog's database is well organized and harmonized allowing systematic extraction of phenotype genotype associations 27 . We Though we note some very encouraging and promising results for the cancer traits with modest number of cases and controls and with a larger number of variants reported in the NHGRI-EBI GWAS catalog, we also note that the correlation of effect estimates or the PRS-cancer association was not very strong for some cancers with six out of twelve having a PRS OR<1.5 ( Table 2) . This could be due to several causes like limited sample size/power, heterogeneity in the definition of the cancer phenotype, incomplete specification of PRS, differences in allele frequencies in the MGI population, misclassification of ICD-9 codes. To address concerns with misclassification we conducted detailed chart review of 50 randomly sampled cases with at least one neoplasm diagnosis and verified their primary and secondary cancer diagnosis. We could verify 149 of the 151 diagnoses and 49/50 patients had accurate record of their cancer diagnosis. Based on this we conclude that the rate of misclassification will likely be low for ICD 9 codes associated with cancer.
In this paper, we have focused on cancer traits. The low misclassification rate of cancer traits, typical within academic health and cancer centers, along with effective sensitivity analyses partly protect the results against imprecise case definitions and confounding.
For non-cancer disease traits, more stringent ICD-9 defined cases, e.g., by repeated ICD-9 diagnoses, balanced with adequate sample sizes might alleviate the biases from case misclassification. Future analysis will need to control for potentially different levels of misclassification error across phenotypes.
Our phenome comprised a total of 1,711 ICD9-based phenotypes and by its implemented design of hierarchical phenotypes with different levels of specificity include a certain degree of redundancy. While we applied the multiple testing correction for 1,711 performed tests, we acknowledge that this threshold might be too conservative.
For examples, we estimated a maximal set of 1,452 phenotypes with all pair-wise correlations r 2 < 0.5 before applying any exclusion criteria to the controls. In addition, the PheWAS approach often applies similar exclusion criteria to related phenotypes and thereby further reduces the actual independence of case control studies. Future studies, which determine the effective number of independent tests in such a phenome-wide analysis, will need to be undertaken
Besides the ICD-9 codes used for case and control definitions, EHR databases generally contain vast amount of additional patient information including ICD-10 codes, temporal laboratory tests, drug prescriptions, inpatient and outpatient records, etc.
Future analyses that leverage these heterogeneous data sources that might be predictive of disease outcomes could further improve disease risk predictions. It will be interesting to study whether PRS for cancer risk behaviors like smoking, alcohol and obesity predict cancer phenotypes. Tailored and validated models capable of integrating multiple sources of data for predicting risks of disease will be crucial. This initial paper provides a framework for the exploration of genetic risk profiles of specific cancer types by using structured and unstructured content of their electronic health records that in the future can be extended by informative molecular and environmental data.
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